

Certificate of Analysis

Product: DOAC-Remove 20 (A) or 50 (B) or 250 (C) tablets

Art. No.: 5D-82410A/B/C

Lot: 010104A/B/C

Expiration Date: 2024-03-01

Description: DOAC-REMOVE™ tablets are intended to be used for removal of Direct Oral Anticoagulant (DOAC) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban and edoxaban. Also removes argatroban. There is no significant effect on clotting factors.

Presentation: 20 (A), 50 (B) or 250 (C) tablets in a vial. Ready to use. Contains activated carbon, specially formulated with additives.


Storage: Store in a dry place at ambient (15-30°C) in its original packaging.

Analytical Data:

	<u>Specification</u>	<u>Results</u>
Weight (n=100):	18 - 22 mg/tablet	pass
Rivaroxaban binding:	≥ 1200 ng/mL	pass
Apixaban binding:	≥ 1000 ng/mL	pass
Edoxaban binding:	≥ 1000 ng/mL	pass
Dabigatran binding:	≥ 1200 ng/mL	pass

2019-07-14

Signed,



Urs Peter Geiger